Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754751 | 0.97 | HTR6 (0.75) | HTR6KCNH2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL3742287 | 0.85 | HTR6 (0.62) | HTR6KCNH2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL3742336 | 0.84 | HTR6 (1.00) | HTR6KCNH2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL3753998 | 0.81 | HTR6 (0.58) | HTR6KCNH2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL7047971 | 0.81 | HTR6 (0.53) | HTR6KCNH2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL7047968 | 0.77 | HTR6 (0.50) | HTR6KCNH2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL3753597 | 0.76 | HTR6 (0.66) | HTR6KCNH2ALDH1A1 | |
| SCHEMBL3744515 | 0.76 | HTR6 (0.74) | HTR6KCNH2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL3761881 | 0.74 | HTR6 (0.81) | HTR6KCNH2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL3754246 | 0.71 | HTR6 (0.77) | HTR6KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838518-B2 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| EP-1476151-B1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORGANON NV (NL) | 2008-07-16 | — | — | EP | disclosed |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | MERCK SHARP & DOHME B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | TPH1, HTR1A, HTR1D | HTR6 12/4885KCNH2 718/4885ALDH1A1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.